Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas,single‐hormone artificial pancreas,or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label,randomised, crossover,controlled trial |
| |
| Authors: | Ahmad Haidar PhD Laurent Legault MD Martin Ladouceur PhD Rémi Rabasa‐Lhoret MD PhD |
| |
| Affiliation: | 1. Faculty of Medicine, Department of Biomedical Engineering, McGill University, Montréal, Québec, Canada;2. Faculty of Medicine, Division of Endocrinology and Metabolism, McGill University, Montréal, Québec, CanadaAll authors contributed equally to this work;3. Montreal Children's Hospital, McGill University Health Centre, Montréal, Québec, Canada;4. The Research Center of the Université de Montréal Hospital Center, Montréal, Québec, Canada;5. Département de Médecine Sociale et Préventive, School of Public Health, Université de Montréal, Montréal, Québec, Canada;6. Institut de recherches cliniques de Montréal, Montréal, Québec, Canada;7. Faculty of Medicine, Nutrition Department, Université de Montréal, Montréal, Québec, Canada;8. Montreal Diabetes Research Center, Montréal, Québec, Canada |
| |
| Abstract: | |
| |
| Keywords: | artificial pancreas, closed‐loop insulin delivery, glucagon hypoglycaemia insulin therapy randomised trial type 1 diabetes |
|
|
